Skip to content

Delcath Systems DCTH Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

Immunome logo
ImmunomeIMNM
$0

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's proceeds from warrant exercises.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's proceeds from warrant exercises?
Delcath Systems (DCTH) reported proceeds from warrant exercises of $0 in Q1 2026.
How has Delcath Systems's proceeds from warrant exercises changed year-over-year?
Delcath Systems's proceeds from warrant exercises decreased by 100.0% year-over-year, from $2.39M to $0.
What is the long-term trend for Delcath Systems's proceeds from warrant exercises?
Over 2 years (2021 to 2024), Delcath Systems's proceeds from warrant exercises has grown at a 310.0% compound annual growth rate (CAGR), from $2.46M to $41.32M.
What does proceeds from warrant exercises mean?
Reflects the cash proceeds received when holders of warrants exercise their rights to purchase company stock at a predetermined price. This serves as a source of non-dilutive capital that strengthens the balance sheet as the company achieves milestones.